Abhishek Pathak, Professor at the Indian Army, shared a post on X:
“What after Osimertinib failure?
Results from MARIPOSA 2.
PFS advantage at best. Did Lazertinib really help?”
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared this post, adding:
“Chemo plus ami will be the new standard, approved by FDA/EMA.
No lazertinib required…”
Sources: Abhishek Pathak/X and Antonio Passaro/X